Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection

被引:34
作者
Fu, Wei [1 ]
Song, Zhiqiang [1 ]
Zhou, Liya [1 ]
Xue, Yan [1 ]
Ding, Yu [1 ]
Suo, Baojun [1 ]
Tian, Xueli [1 ]
Wang, Li [1 ]
机构
[1] Peking Univ, Hosp 3, Dept Gastroenterol, 49 North Garden Rd, Beijing 100191, Peoples R China
关键词
Helicobacter pylori; Eradication; Amoxicillin; Cefuroxime; Safety; Compliance; PENICILLIN-ALLERGIC PATIENTS; TRIPLE PLUS BISMUTH; ANTIBIOTIC-RESISTANCE; THERAPY; MANAGEMENT; CEPHALOSPORINS; CLARITHROMYCIN; METRONIDAZOLE; MULTICENTER; EFFICACY;
D O I
10.1007/s10620-017-4564-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The eradication of Helicobacter pylori infection remains a challenge, especially in the patients unsuitable to take penicillin. Cephalosporin has the potential to replace amoxicillin for H. pylori eradication. To compare the effectiveness, safety, and compliance of amoxicillin- and cefuroxime-containing quadruple regimens in treatment-na < ve patients. In this open-label randomized control study, 400 patients with H. pylori infection were divided into amoxicillin-containing (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) or cefuroxime-containing (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) quadruple therapy groups. The safety and compliance were assessed 1-3 days after eradication. Urea breath test was performed 8-12 weeks after eradication to determine treatment outcome. The baseline data including antibiotic resistance were well matched between the two groups. The eradication rates between amoxicillin- and cefuroxime-containing quadruple therapy groups were not significantly different [intention-to-treat analysis: 83.5% (95% confidence interval 78.3-88.7%) vs. 81.0% (75.5-86.5%), P = 0.513; modified intention-to-treat analysis: 90.3% (86.0-94.6%) vs. 88.5% (83.9-93.2%), P = 0.586; per-protocol analysis: 91.6% (87.5-95.7%) vs. 89.8% (85.3-94.3%), P = 0.560]. The incidence of adverse effects (18.4 vs. 20.1%, P = 0.678) and compliance (94.7 vs. 94.2%, P = 0.813) were also similar. Variate analyses showed that antibiotic resistance and poor compliance were the independent risk factors for eradication failure. Esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime achieved similar and relatively satisfactory cure rates, safety, and compliance in first-line H. pylori eradication. Cefuroxime may be a good alternative medicine for eradication instead of amoxicillin for the patients unsuitable to take penicillin.
引用
收藏
页码:1580 / 1589
页数:10
相关论文
共 30 条
[1]   Susceptibility of Helicobacter pylori to antibiotics in Chinese patients [J].
Bai, Peng ;
Zhou, Li Ya ;
Xiao, Xiu Mei ;
Luo, Yang ;
Ding, Yu .
JOURNAL OF DIGESTIVE DISEASES, 2015, 16 (08) :464-470
[2]   THE USE OF CEPHALOSPORINS IN PENICILLIN-ALLERGIC PATIENTS: A LITERATURE REVIEW [J].
Campagna, James D. ;
Bond, Michael C. ;
Schabelman, Esteban ;
Hayes, Bryan D. .
JOURNAL OF EMERGENCY MEDICINE, 2012, 42 (05) :612-620
[3]   Classification and grading of gastritis - The updated Sydney System [J].
Dixon, MF ;
Genta, RM ;
Yardley, JH ;
Correa, P ;
Batts, KP ;
Dahms, BB ;
Filipe, MI ;
Haggitt, RC ;
Haot, J ;
Hui, PK ;
Lechago, J ;
Lewin, K ;
Offerhaus, JA ;
Price, AB ;
Riddell, RH ;
Sipponen, P ;
Solcia, E ;
Watanabe, H .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (10) :1161-1181
[4]   Role of bismuth in improving Helicobacter pylori eradication with triple therapy [J].
Dore, Maria Pina ;
Lu, Hong ;
Graham, David Y. .
GUT, 2016, 65 (05) :870-878
[5]  
Fagoonee S, 2013, PANMINERVA MED, V55, P309
[6]   Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection Time Trends in a Spanish Multicenter Study of 1000 Patients [J].
Gisbert, Javier P. ;
Perez-Aisa, Angeles ;
Bermejo, Fernando ;
Castro-Fernandez, Manuel ;
Almela, Pedro ;
Barrio, Jesus ;
Cosme, Angel ;
Modolell, Ines ;
Bory, Felipe ;
Fernandez-Bermejo, Miguel ;
Rodrigo, Luis ;
Ortuno, Jesus ;
Sanchez-Pobre, Pilar ;
Khorrami, Sam ;
Franco, Alejandro ;
Tomas, Albert ;
Guerra, Ivan ;
Lamas, Eloisa ;
Ponce, Julio ;
Calvet, Xavier .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2013, 47 (02) :130-135
[7]   Hp-normogram (normo-graham) for Assessing the Outcome of H-pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype [J].
Graham, David Y. .
HELICOBACTER, 2016, 21 (02) :85-90
[8]   Helicobacter pylori treatment in the era of increasing antibiotic resistance [J].
Graham, David Y. ;
Fischbach, Lori .
GUT, 2010, 59 (08) :1143-1153
[9]   Effect of Fluoroquinolone Resistance on 14-day Levofloxacin Triple and Triple Plus Bismuth Quadruple Therapy [J].
Liao, Jingxian ;
Zheng, Qing ;
Liang, Xiao ;
Zhang, Wei ;
Sun, Qinjuan ;
Liu, Wenzhong ;
Xiao, Shudong ;
Graham, David Y. ;
Lu, Hong .
HELICOBACTER, 2013, 18 (05) :373-377
[10]   Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial [J].
Liou, Jyh-Ming ;
Chen, Chieh-Chang ;
Chen, Mei-Jyh ;
Chen, Chien-Chuan ;
Chang, Chi-Yang ;
Fang, Yu-Jen ;
Lee, Ji-Yuh ;
Hsu, Shih-Jer ;
Luo, Jiing-Chyuan ;
Chang, Wen-Hsiung ;
Hsu, Yao-Chun ;
Tseng, Cheng-Hao ;
Tseng, Ping-Huei ;
Wang, Hsiu-Po ;
Yang, Ueng-Cheng ;
Shun, Chia-Tung ;
Lin, Jaw-Town ;
Lee, Yi-Chia ;
Wu, Ming-Shiang .
LANCET, 2013, 381 (9862) :205-213